Q3 Revenue Collapses to $1.3M as BARDA Contract Winds Down; CSO Retires
SIGA sits 15% above its 52-week low of $2.83.
Summary
Third-quarter revenue fell to $1.3M from $2.6M a year ago, and the nine-month top line dropped to $48.6M from $90.8M, as the 19C BARDA procurement order was fully delivered ($26M of IV TPOXX to the SNS) and no replacement U.S. government contract is in place. The quarter produced a $2.9M net loss (-$0.04 per share) versus a $6.4M loss a year earlier, while nine-month net income of $6.1M ($0.09 per share) is down sharply from $28.7M ($0.40). Cash stands at $116.4M, down from $155.0M at year-end after the $0.60 special dividend paid in April. Management says it is still negotiating a new TPOXX procurement contract with the U.S. Government and is leaning on international deals — the October Canadian DND award of up to roughly $15M, of which about $9M is firm over three years. Separately, EVP and Chief Scientific Officer Dennis Hruby retires effective today after more than 30 years, staying on as an advisor. The story is the revenue cliff: with the U.S. stockpile order exhausted, the thesis now rests entirely on a new BARDA contract that has not been signed.
At the time of this announcement, SIGA was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $234.2M. The 52-week trading range was $2.83 to $7.44. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.